Mink Therapeutics Inc (INKT)
MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease
MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease
The Latest from NRC Health | AI and the trust ecosystem, NRC Healths new podcast, and so much more!
Auxly Reviews 2025 Milestones and Provides 2026 Outlook
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
ENvue Medical to Ring the Nasdaq Opening Bell on Wednesday, January 14th, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc. - VTYX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGO
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Air Products and Chemicals, Inc. - APD
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO